Latest:
SCLC: Rechallenging With Chemotherapy + I/O
Anne Chiang, MD, PhD, renowned expert in thoracic oncology, guides a discussion on whether to rechallenge with chemotherapy + I/O after progression of small cell lung cancer.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Hossein Borghaei, DO, MS, Fox Chase Center at Temple Health
Latest:
SCLC: Second-Line Options and Supportive Care
Key opinion leaders in thoracic oncology provide insights into second-line treatment for patients with relapsed/refractory small cell lung cancer and comment on the role of trilaciclib in managing cisplatin-associated neutropenia.
Howard Jack West, MDest, MD
Latest:
E-patients: The Genie is Out of the Bottle
Melissa received a metastatic lung cancer diagnosis just a few weeks after celebrating her 40th birthday. Within hours of hearing her diagnosis from her primary care physician, she started searching the Internet about her disease and what to expect in terms of treatments.
Howard L. Kaufman, MD
Latest:
Dr. Kaufman on T-VEC in Melanoma
Howard L. Kaufman, MD, chief surgical officer, associate director for Clinical Science, surgical oncologist, Rutgers Cancer Institute of New Jersey, discusses oncolytic immunotherapy talimogene laherparepvec (T-VEC; Imlygic) for treatment of patients with melanoma, as well as the agent's side effect profile.
Howard L. Kaufman, MD, FACS,
Latest:
The Search for Immune-Specific Biomarkers Is in Full Swing
An improved understanding of how the immune system recognizes and eradicates cancer cells, along with advances in drugs that effectively promote antitumor immune responses, is revolutionizing the field of cancer therapy.